The blood pressure medication recall 2026 list runs to 20 FDA enforcement-report entries so far: brand-name Diovan 160 mg, metoprolol succinate ER from Teva and Ascend, Teva’s clonidine patch, amlodipine-olmesartan, furosemide, chlorthalidone, enalapril, prazosin, doxazosin and a bisoprolol-HCTZ tablet.
All but one are Class II; the doxazosin entry is Class III. Each was firm-initiated and is still listed as ongoing in openFDA enforcement data as of August 27, 2026.
The reasons on record: tablets that dissolve wrong, nitrosamine limits exceeded, an organic impurity out of range, a foreign substance, an unapproved raw material and a wrong imprint.
The 2026 recall list, drug by drug
| Drug and strength | Recalling firm | Recall began | Reason on FDA record |
|---|---|---|---|
| Diovan (valsartan) 160 mg, 90-count | Novartis | Aug 4, 2026 | Failed dissolution |
| Amlodipine/olmesartan 10/20 mg and 5/40 mg | Ascend Laboratories | Jul 8 and May 5, 2026 | Olmesartan content below spec |
| Chlorthalidone 25 mg | Inventia Healthcare | Jun 5, 2026 | Failed dissolution |
| Metoprolol succinate ER 25 mg | Ascend Laboratories | Apr 27, 2026 | Failed dissolution |
| Enalapril maleate 20 mg, 1,000-count | JB Chemicals | Apr 23, 2026 | Organic impurities out of spec |
| Prazosin 1, 2 and 5 mg | Appco Pharma | Mar 27, 2026 | N-nitroso-prazosin above limit |
| Furosemide 80 mg | Leading Pharma | Mar 20, 2026 | N-nitroso-furosemide above limit |
| Clonidine patch 0.1, 0.2 and 0.3 mg/day | Teva (Actavis) | Mar 19, 2026 | Unapproved raw material |
| Metoprolol succinate ER 25, 50, 100 and 200 mg | Teva | Jan 29, 2026 | Failed dissolution |
| Doxazosin 4 mg, 1,000-count | Unichem | Jan 21, 2026 | Wrong imprint (Class III) |
| Bisoprolol/HCTZ 2.5/6.25 mg | Unichem | Jan 21, 2026 | N-nitroso-bisoprolol above spec |
| Furosemide 40 mg, 1,000-count | Graviti Pharmaceuticals | Jan 10, 2026 | Foreign substance |
Why they were pulled: three kinds of failure
Failed dissolution leads, behind the Diovan, both metoprolol, both amlodipine-olmesartan and the chlorthalidone recalls. The test times how fast a tablet releases its drug in a lab bath; fail it and the dose on the bottle may not be the dose your body receives.
Nitrosamines are the second group. Bisoprolol-HCTZ, prazosin and 80 mg furosemide each exceeded the limit for a drug-specific N-nitroso compound, the impurity family behind the 2018 valsartan recalls. The FDA publishes acceptable intake limits for them.
The remaining four reasons, a foreign substance, an unapproved raw material, an out-of-range impurity test and a wrong imprint, each apply to a single product.
Lot numbers and NDC codes for each entry sit in the FDA’s weekly enforcement reports. The Teva metoprolol recall alone covers 112,327 bottles; the clonidine patches, 300,133 cartons.
What Class II means when it is your prescription
Under the FDA’s recall definitions, Class II means possible temporary or medically reversible harm, or a remote chance of serious harm. Class III means adverse effects are unlikely.
The stop-immediately tier is Class I, and no 2026 blood pressure entry we found sits there.
Recall notices for these drugs routinely tell patients to keep taking the medicine and talk to a pharmacist or prescriber before switching. Stopping a blood pressure drug abruptly carries its own risk.
How to check your own bottle
Your pharmacy label rarely shows the manufacturer’s lot number. Call the pharmacy with the drug name and strength and ask them to match your fill against the recalled lots; they hold the NDC, the same label detail that separates vitamin D2 from D3.
Watch for changes while you wait. Light-headedness on getting up is one sign pressure is moving, and what happens when you stand up too fast explains that reflex. A home reading that climbs across a week is the other.
Supplements do not cover a gap left by a recalled prescription. If you take magnesium taurate for heart support alongside your medication, keep taking the prescription with it.
This article is general information, not medical advice. Decisions about any prescription belong with your pharmacist or prescriber.
Was losartan recalled in 2026?
Not in FDA enforcement data through August 27, 2026. The angiotensin receptor blocker entries this year are Diovan 160 mg and Ascend’s amlodipine-olmesartan; losartan, irbesartan and telmisartan do not appear.
Does the Diovan recall cover every strength?
No. It covers one lot, AV5913C, of 160 mg tablets in 90-count bottles, NDC 0078-0359-34, expiry 6/2027, distributed nationwide in the US.
Should I stop taking a recalled blood pressure pill?
Not on your own. Ask your pharmacy whether your fill came from an affected lot, and ask your prescriber about a replacement before skipping a dose.